What to expect from payer, provider Q3 earnings
The intense volume of COVID-19 patients that came from the delta surge will likely influence winners and losers for the third quarter. Results ramp up this week.
Walmart, Transcarent partner to pitch self-insured employers
The retail giant will make its low-cost prescription drugs, along with its optical, telehealth and other services available to self-insured employers while leveraging Transcarent’s digital platform.
Walmart, Transcarent partner on product for self-insured employers
The retail giant will make its low-cost prescription drugs, along with its optical, telehealth and other healthcare services available to self-insured employers while leveraging Trascarent’s digital platform to direct patients to the right sites of care.
One Medical elbows into chronic condition management with new program
With the launch, the concierge medical provider enters a crowded market, as a number of programs are already looking to lower costs and improve outcomes for the high-need chronic disease population.
Doctor on Demand, Grand Rounds rebrand as Included Health to compete in crowded benefits space
Seven months after announcing plans to merge, virtual care company Doctor on Demand and clinical navigator Grand Rounds are launching a new brand for their combined company.
Zelis helps address new NSA and TiC regulations
Learn more about innovative solutions that can help you comply with new regulations.
FDA panel endorses second shot for adults who received J&J vaccine
Agency advisers unanimously supported offering a second dose of J&J’s coronavirus vaccine to adults who previously received it, though guidance could change as regulators evaluate mixing boosters.
Walgreens invests $330M in CareCentrix in post-acute care bet
Walgreens significantly invested in two companies to meet its long-term strategy, with one focused on primary care and the other on post-acute care.
Biden circling former FDA chief Califf to again lead agency: report
The Washington Post reported the administration was “closing in” on the choice, citing unnamed sources. Still, the White House declined to comment and he could face opposition from Senate Democrats.
Medtechs need strategy to prevent bias in AI-machine learning-based devices: FDA
The agency is mulling the types of information medtechs might include in labeling for such devices to support transparency. A Philips rep worried about the pitfalls of “information overload.”